Stockscreener 앱 받기
442.96
0.87%
-3.87
시간 외 거래:
442.00
-0.96
-0.22%
전일 마감가:
$446.83
열려 있는:
$443.17
하루 거래량:
1.15M
Relative Volume:
0.88
시가총액:
$112.43B
수익:
$12.34B
순이익/손실:
$4.34B
주가수익비율:
26.26
EPS:
16.8685
순현금흐름:
$3.71B
1주 성능:
+1.04%
1개월 성능:
+3.06%
6개월 성능:
+0.21%
1년 성능:
-1.67%
1일 변동 폭
$441.72
$448.69
1주일 범위
$420.01
$453.16
52주 변동 폭
$362.50
$507.92
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
442.96 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.34 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.41 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.16 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.49 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-03-10 | 재확인 | Oppenheimer | Outperform |
| 2026-02-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - Yahoo Finance
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio - Barchart.com
News | Not built for eternity: Design technique looks to avoid permanence - CoStar
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference - BioSpace
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Mixed Recent Returns And Long Term Shareholder Gains - Yahoo Finance
FDA accepts Vertex's BLA for povetacicept in IgA nephropathy - MSN
VRTX Stock Quote Price and Forecast - CNN
Vertex Pharmaceuticals (VRTX) Reveals Promising Cystic Fibrosis Treatment Data - GuruFocus
Carmen R. Bozic sells shares at VRTX (NASDAQ: VRTX) - Stock Titan
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference - Via TT
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $550 - Moomoo
Ixlayer rolls out digital acute pain management platform in collaboration with Vertex Pharmaceuticals - Fierce Healthcare
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities - NAI500
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Sustained momentum drives Vertex Pharmaceuticals stock higher despite signs of overbought conditions - Traders Union
RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $543 - Moomoo
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth - AOL.com
The Best Stocks to Invest $500 in Right Now - AOL.com
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 - BioSpace
Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
MFS Core Equity Portfolio's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex (VRTX) legal chief sells 828 shares in pre-set 10b5-1 trade - Stock Titan
Vertex CEO joins Goldman Sachs healthcare fireside chat June 10 - Stock Titan
Vertex Pharma stock (US92532F1003): Insider sale by CMO draws focus as shares hold near recent level - AD HOC NEWS
Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune
Vertex stock down nearly 8% in 3 months: Time to buy or stay cautious? - MSN
Madrigal Pharmaceuticals Could Become The Next Vertex - Seeking Alpha
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc stock (US92532F1003): shares slip after insider sales and FDA update on p - AD HOC NEWS
Is Vertex Pharmaceuticals (VRTX) Offering An Opportunity After Recent Share Price Consolidation? - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement - TradingKey
Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing - marketscreener.com
Vertex (VRTX) CMO executes 1,974-share planned sale, retains holdings - Stock Titan
Why is Vertex Pharmaceuticals stock down today? - Traders Union
Should FDA’s IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticals’ (VRTX) Investment Narrative? - Yahoo Finance
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy - Yahoo Finance
Vertex Pharmaceuticals Inc stock (US92532F1003): insider sales and Q1 2026 figures in focus - AD HOC NEWS
Acute Pain Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Vertex Pharma, Heron Therapeutics, Neumentum, Cali Biosciences - Barchart.com
Vertex Pharma stock (US92532F1003): FDA accepts povetacicept filing as shares trade steady on Nasdaq - AD HOC NEWS
Vertex Pharmaceuticals stock: Is VRTX underperforming the healthcare sector? - MSN
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy - BioSpace
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals shares dip amid rising selling pressure - Traders Union
Vertex Pharmaceuticals (NASDAQ: VRTX) insider Joy Liu reports share sales - Stock Titan
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector? - Barchart.com
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.79%
0.26%
자본화:
|
볼륨(24시간):